RxDoctor Payments Data

Andrew Glatt, MD

Internal Medicine · Burlingame, CANPI 1487684924

Payments from drug & device makers

$10,878in general payments, 2019–2025

Across 567 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$938
  • Boehringer Ingelheim$797
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$586
  • Pfizer$573
  • AstraZeneca$418
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$10,76899%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)103$1,757
Novo Nordisk49$938
Boehringer Ingelheim41$797
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$586
Pfizer25$573
AstraZeneca20$418
Lilly USA, LLC20$405
Indivior Inc.23$381
Sunovion Pharmaceuticals Inc.30$362
Astellas Pharma US Inc16$321
Takeda Pharmaceuticals U.S.A., Inc.18$293
Otsuka America Pharmaceutical, Inc.15$279
Collegium Pharmaceutical, Inc.13$261
Alkermes, Inc.11$250
Johnson & Johnson11$228
GSK8$202
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$186
Amgen6$174
Merck9$165
Teva Pharmaceuticals USA, Inc.7$164
Lundbeck LLC6$134
Redhill Biopharma Inc.8$134
Seqirus USA Inc7$122
Idorsia Pharmaceuticals US Inc6$119
Bausch Health US, LLC5$107
Orexo US, Inc.6$101
Eisai Inc.6$100
Biohaven Pharmaceutical Holding Company Ltd.4$96
Biodelivery Sciences International, Inc.5$93
Axsome Therapeutics, Inc.3$89
Biohaven Pharmaceuticals, Inc.3$87
Braeburn Inc.3$71
Bayer3$71
Hikma Pharmaceuticals USA3$56
Kowa Pharmaceuticals America, Inc.3$55
Boston Scientific2$53
Vanda Pharmaceuticals Inc.2$53
Covis Pharma GmbH1$50
Esperion Therapeutics, Inc.2$46
Assertio Therapeutics, Inc.3$44
E.r. Squibb & Sons, L.L.C.2$43
Edwards Lifesciences2$42
MDD US Operations, LLC2$35
Novartis2$32
Avanir Pharmaceuticals, Inc.1$31
Phathom Pharmaceuticals, Inc.1$26
Scilex Pharmaceuticals Inc.1$25
Almatica Pharma LLC1$24
Alfasigma USA, Inc.1$23
Jazz Pharmaceuticals Inc.1$23
Abbott1$21
Kaleo, Inc.1$21
Sanofi-aventis U.S. LLC1$20
Ironwood Pharmaceuticals, Inc1$18
Masimo Corporation1$17
Arbor Pharmaceuticals, Inc.1$16
Smith+Nephew1$16
Circassia Inc.1$15
Nevro Corp.1$12

How this compares

$10,878 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$224,278
Medicare patients
407
Services billed
1,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$93,558
OzempicSemaglutide64$74,425
JardianceEmpagliflozin56$66,205
RybelsusSemaglutide27$44,914
TrulicityDulaglutide28$41,853
FarxigaDapagliflozin Propanediol38$38,231
CreonLipase/Protease/Amylase15$35,968
XareltoRivaroxaban35$29,899
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,102
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl89$23,505
MounjaroTirzepatide22$22,907
JanuviaSitagliptin Phosphate13$18,803
MyrbetriqMirabegron15$10,783
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,652
BelsomraSuvorexant13$8,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$938$119,33991 claims
PfizerEliquis$573$93,55889 claims
Boehringer IngelheimJardiance$797$66,20556 claims
Lilly USA, LLCTrulicity, Mounjaro$405$64,76150 claims
AbbVieCreon, Linzess, Synthroid$1,757$47,17777 claims
AstraZenecaFarxiga$418$38,23138 claims
GSKTrelegy Ellipta, Anoro Ellipta$202$36,75453 claims
Johnson & JohnsonXarelto$228$29,89935 claims
MerckJanuvia, Belsomra$165$27,71026 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine$56$25,664102 claims
Astellas Pharma US IncMyrbetriq$321$10,78315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →